Zydus Lifesciences Limited — Updates, 16-07-2025: Press Release

Zydus Lifesciences announced the successful closure of a Remote Regulatory Assessment (RRA) by the USFDA at its Matoda, Gujarat formulations manufacturing facility. This assessment, conducted for a Prior Approval Supplement of Atorvastatin Calcium Tablets, concluded with no observations. The facility received a positive assessment for approval. This is a significant operational positive, removing a potential regulatory hurdle and enabling potential market expansion for these important products, which could bolster future revenue streams.